|
In 1968 the Scind Laboratories of
the University of San Francisco (USA) carried out amygdalin trials on 400
rats with Walker’s carcinoma (200 treated and 200 controls). The dose
was 500 mg per day. The results indicated a significantly longer life for
80% of the animals receiving amygdalin. The conclusion was that “the
results undoubtedly indicate some effectiveness against animal tumors.”
(Rosenberg)
Dr T. Metianu of the Pasteur
Institute of Paris, France, conducted trials in association with the
French Ministry of Agriculture on human cancers transplanted in mice. The
researchers administered daily doses of 500 mg per kg of body weight and
were able to achieve 100% increase in life expectancy and the total
inhibition of tumor growth. (Rosenberg)
The East German Von Ardenne
Institute of Dresden investigated the effects of bitter almonds amygdalin
taken ad libitum in a chow diet in mice with implanted Ehrlich ascites
carcinoma. The researchers observed significant increases in life
expectancy as well as inhibition of tumor growth. (Rosenberg)
The following is a study presented
to the Sixth International Cancer Congress, Sao Paulo, Brazil, July 1954
by Ettore Guidetti, Professor of Pharmacology, University of Turin Medical
School.
Laetrile was administered to a
group of 5 males and 5 females with an average age of 45. The diagnosis
was adenocarcinoma (tumor of the glands) of the breast in 4 cases,
Hodgkins disease 3, cancer of the lung 1, cancer of the prostate 1 and
cancer of the pancreas and omentum (layer of tissue attached to the
stomach)1.
The average period of treatment
with laetrile was 17.5 weeks with an average total dose of 46.2 gms.
Dramatic relief of pain resulted
in all 10 cases. In 5 cases pain disappeared completely and in the other 5
it was definitely reduced. Narcotics were discontinued in 5 of the 7 cases
in which they were used. After 7 injections the fetor (unpleasant smell)
from an ulcerating adenocarcinoma of the breast disappeared and the
discharge ceased.
In all but 2 cases the blood
picture was greatly improved after the use of laetrile. There was no
indication of agranulocytosis (deficiency of blood cells) or other
hematogenous (blood) toxicity.
There was an average increase in
the red blood cell count of 15% and a 2% decrease in the white blood cell
count, the latter being regarded as statistically insignificant. The
average hemoglobin (the substance within red blood cells responsible for
their colour) showed a 6% increase after treatment. Urinalysis was
negative and kidney function was not altered or affected by the use of
laetrile.
In conclusion, the use of laetrile
in 10 cases of inoperable cancer, all with metastases, provided dramatic
relief of pain, discontinuance of narcotics, control of fetor, improved
appetite and reduction of adenopathy. The results suggest regression of
the malignant lesion.
A fall of blood pressure occurred
in all cases after the administration of laetrile. This side effect was
easily avoided by using phenylephrine hydrochloride in the same syringe
with the laetrile solution. No other side effects were noted except slight
itching and a sensation of heat in the affected areas which was transitory
in all cases.
Comparison before and after
hemograms showed definite improvement in the red blood cell count and
hemoglobin in most cases. Differential blood counts and urinalyses were
entirely negative. The findings present an image of cancer which is
consistent with the trophoblastic thesis.
The study goes on to describe in
some detail the circumstances, treatment and results for each of the 10
individuals.
The following is a report given to
the 9th International Cancer Congress, Tokyo, October 1966 by
B. Rossi, E. Guidetti and C. Deckers entitled Clinical Trial of
Chemotherapeutic Treatment of Advanced Cancers with Laetrile (L-Mandelonitrile-Beta-Diglucoside).
From 1954 to 1966 they gave 150
patients the above mentioned therapy chiefly at the Turin and Milan
hospitals. All patients were in the terminal stage of the disease, the
majority of them prey to cachezia (abnormally low weight, weakness and
general bodily decline associated with chronic disease). All other
therapies had failed.
28 cases reacted in an objectively
favourable manner, by which they meant diminution of the volume of the
tumor or at least all interruption of its evolution, improvement in the
roentgenographic picture, (i.e. photographs produced by xrays) and
improvement in laboratory findings.
62 cases showed a more or less
distinct subjective improvement and 45 reacted negatively. They stressed
that the majority of the cases were simultaneously subjected to an
immunotype therapy which might have had some bearing on the number of
positive results observed.
The remaining 15 involved
neoplasms (an uncontrolled growth of tissue, in other words a tumor) of
the pleura (the cover of the lungs) with effusion (fluid that has escaped
into a bodily cavity). Laetrile was injected into the pleural cavity (the
space between the pleura).
In these cases they observed their
best results with reduction and on occasion the complete disappearance of
the effusion, associated with a distinct improvement in the patient’s
condition.
They concluded that on the basis
of their clinical trial, they were able to state that laetrile may be
considered an extremely useful drug for palliative medical treatment of
malign neoplasms from the standpoint of both its therapeutic effect and
its very low toxicity.
|
